The European Circular Bio­economy Fund, which aims to provide financing for innovative circular bioeconomy companies and projects in the EU and in countries associated with the Horizon 2020 programme, will be headed by Michael Brandkamp.

In clinical trials, BO-112, the first cancer immunotherapeutic developed in Spain, shrinked tumour volume by 15% in 56% of patients. © BIOncoTech Therapeutics

Madrid-based RNA specialist Bioncotech Therapeutics has entered into a Phase II clinical trial collaboration with a MSD subsidiary.

© University Hospital Bern/J. Gralla

Swiss surgeons have significantly improved mechanical removal of blood clots in stroke patients by intra-arterial administration of the thromolytic urokinase.

At the 15th Annual Scrip Awards, Mogrify Chair Jane Osbourn has been presented with the Lifetime Achievement Award. She received the award in recognition of her outstanding contribution to the biotech industry throughout her career.

Adverse effects triggered by unmodified IL-2. © Synthorx Inc

Sanofi will acquire Synthorx Inc to expand its  immuno-oncology pipeline with THOR-707, an optimised IL-2 candidate.

Meatable managers in the lab. @ Meatable

Meatable NV, a specialist for cultivated meat, has raised an additional US$10m in seed funding, bringing the company’s total funding to US$13m.

Claus Haberda will be the new Managing Director at Roche Diagnostics GmbH, succeeding Ursula Redeker, who will return to Basel.

© Pixabay

Médecins Sans Frontières (MSF) called on the GAVI Vaccine Alliance not to pay huge subsidies to Big Pharma companies for pneumococcal vaccine

ICT01 is an activating mAb targeting the extracellular domain of BTN3A that leads to activation and trafficking of ?9?2 T cells out of the circulation.  ICT01 has been shown to promote an anti-tumor immune response against a range of cancers in in vitro and in mouse tumor models. In primates, ICT01 rapidly occupies its target and specifically activates ?9?2 T cells with a good safety profile that supports clinical testing. © ImCheck Therapeutics SAS

T cell agonist specialist ImCheck Therapeutics will use €48m (US$53m) from a Series B financing to push clincial pipeline of antibodies activating gamma-delta T-cells.

Pierre Fabre SA and Puma Biotechnology, Inc. have broadened the geographic coverage of their license agreement on commercialisation of Nerlynx® (neratinib).